Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...
Earnings call Recursion ended Q2 2025 with $533M in cash, a 35% reduction in expected cash burn by 2026 versus 2024, and reaffirmed guidance for over $100M in partnership inflows by end of 2026. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results